Sign in

Robert Allen, Ph.D.

Chief Scientific Officer (CSO) at Invivyd
Since April 11, 2023
Age
56 years
Education
Earned a B.S. in Biology from Rhodes College, an M.S. in Applied Biology from Georgia Institute of Technology, and a Ph.D. in Microbiology from Columbia University.
Tenure
Has served as Chief Scientific Officer at IVVD since April 2023 after joining on April 11, 2023 and assuming leadership in advancing the company’s research and development efforts.

Also at Invivyd

About

Dr. Robert Allen, Ph.D. has built a robust career spanning over 30 years in infectious disease research, anchored by his strong academic background from Rhodes College, Georgia Institute of Technology, and Columbia University.

Prior to his role at IVVD, he held senior scientific positions at organizations such as SmartPharm Therapeutics and Sorrento Therapeutics, as well as other industry-leading institutes like SIGA Technologies, honing his expertise in virology and immunotherapy.

Since joining IVVD as Chief Scientific Officer on April 11, 2023, he has played a critical role in steering the company’s research initiatives, including the development of gene-encoded monoclonal antibodies for COVID-19.

His extensive experience and leadership in the biopharmaceutical sector underscore a career dedicated to advancing innovative therapeutic solutions, making him a key asset in the company's strategic pursuits.

Past Roles

OrganizationRoleDate RangeDetails
SmartPharm Therapeutics (a subsidiary of Sorrento Therapeutics) Chief Scientific Officer 2020 to 2023 Led efforts to develop gene-encoded monoclonal antibodies for COVID-19
Sorrento Therapeutics Senior Vice President, Antiviral and Oncolytic Immunotherapy Development 2020 to 2023 Held concurrently with SmartPharm role
Sorrento Therapeutics Head of Oncolytic Immunotherapy 2018 to 2020 N/A
SIGA Technologies Senior Scientific Position N/A N/A
Oregon Translational Research and Development Institute Senior Scientific Position N/A N/A

Fixed Compensation

Data from  FY 2023
Component NameAmountPayment ScheduleAdditional Details
2023 Base Salary$450,000 AnnualizedAnnual base salary
Salary Paid in 2023$325,673 Prorated (start date: April 11, 2023)Reflects prorated salary since employment commenced on April 11, 2023
Relocation Bonus$50,000 One-time paymentProvided to assist with relocation expenses
Equity-Based Awards$1,327,000 Award granted (equity-based)Includes details: 600,000 unexercised options at $1.205 (exp. 4/10/2033) and 400,000 unexercised options at $3.59 (exp. 12/17/2033)

Performance Compensation

Data from  FY 2023

Annual Performance Bonus

MetricValueAdditional Details
Target Bonus Percentage40% Based on annual base salary
Actual Payout$261,370 Prorated for start date (April 11, 2023)
Milestone ThresholdSpecified MilestoneIf achieved, bonus attains 200% of target
Evaluation Period2023Performance period adjusted for prorated start

Cash-Based Incentive Program

MetricValueAdditional Details
Milestone ConditionDose first participant in pivotal clinical trial of VYD222 by September 30, 2023 Achievement of a specific clinical milestone
Actual AchievementAchieved in September 2023 Meeting the milestone triggered the payout
Payout$54,360 Prorated based on employment start date (April 11, 2023) ; no vesting applicable (cash-based)